Understanding PCR Internal Controls: The Published KoMa Example
Examine the purpose of PCR internal controls and discover how KoMa was used in a published RT-PCR protocol to monitor potential inhibition and extraction performance.
Understanding PCR Internal Controls: The Published KoMa Example
Why can a negative molecular result sometimes be misleading? A published RT-PCR study from the Robert Koch Institute provides a practical example of how an artificial RNA control named KoMa was integrated into a laboratory workflow to monitor technical performance and potential inhibition.
A negative PCR signal does not automatically prove that the target was absent. The KoMa example illustrates how a control added before extraction can help researchers distinguish supported negative findings from results affected by sample processing or amplification problems.
Why a molecular test needs more than a target signal
Polymerase chain reaction is widely used to investigate specific genetic sequences. In a qualitative assay, detection of the selected target can provide evidence that the corresponding nucleic acid is present in the analyzed material.
The interpretation of a negative result is more complicated. An absence of detectable amplification might reflect a sample containing no detectable target, but it can also occur when target material is lost during processing or when substances interfere with the amplification reaction.
Biological samples vary considerably in composition. Respiratory specimens, for example, may contain mucus, host material and other substances that influence nucleic acid extraction or downstream enzymatic reactions.
Without additional control information, a laboratory may be unable to distinguish a genuine negative measurement from a technically compromised reaction.
An internal control provides a second molecular observation. Its response helps assess whether specified parts of the test system performed as expected, thereby supporting interpretation of the primary target result.
This principle becomes particularly important when researchers develop assays intended for complex sample matrices or large numbers of specimens.
How KoMa entered the RKI/ZBS1 RT-PCR protocol
In 2021, researchers published a study titled Resource-efficient internally controlled in-house real-time PCR detection of SARS-CoV-2 in Virology Journal.
The work described an internally controlled one-step real-time RT-PCR protocol developed at the Robert Koch Institute for SARS-CoV-2 RNA detection. The protocol combined two independent viral target assays with complementary control systems.
One viral assay targeted the E gene and was paired with KoMa, an artificial nucleic acid control used to assess inhibition and extraction-related problems. The other viral assay targeted a region of orf1ab and was paired with a human c-myc assay.
The researchers used KoMa-containing virus-like particles as external material introduced into the sample processing workflow. This design allowed the control to experience extraction and subsequent amplification rather than being introduced exclusively at the final PCR stage.
KoMa was not itself a SARS-CoV-2 target and its signal was not interpreted as evidence of viral infection. Instead, its expected amplification supplied information about the analytical process.
The primary scientific source is the RKI/ZBS1 study in Virology Journal (2021). Read the full open-access article.
This distinction is essential when discussing KoMa in a scientific article. The published example describes a specific internal control implementation within a validated experimental protocol, not a universal control that can be inserted into every PCR assay without further validation.
Two viral targets and two different quality-control questions
The published protocol used two separate RT-PCR reactions. The first included the SARS-CoV-2 E-gene assay together with KoMa detection, while the second included an orf1ab assay together with human c-myc detection.
This arrangement was scientifically useful because KoMa and c-myc provided different information.
KoMa was an exogenous control introduced into the workflow. Its behavior could help indicate whether extraction performance or reaction inhibition had affected the analytical process.
The c-myc assay, by contrast, detected human nucleic acid. Its measurement offered information related to the presence and recovery of sample-derived material, although the quantity of human nucleic acid could naturally vary between specimens.
| Assay element | Molecular target | Purpose |
|---|---|---|
| E-gene assay | SARS-CoV-2 RNA | Viral target detection |
| KoMa | Artificial control RNA | Monitor extraction-related performance and inhibition |
| orf1ab assay | SARS-CoV-2 RNA | Independent viral target detection |
| c-myc assay | Human nucleic acid | Assess sample-derived nucleic acid detection |
The combined system therefore provided more information than a single viral amplification reaction. By observing both the targets and their associated controls, the researchers could better identify analytical limitations affecting particular samples.
Why adding KoMa before extraction changes its meaning
The timing of control addition determines which technical steps the control can potentially monitor.
If an artificial DNA control is added only to the final PCR mixture, it can provide information about amplification competence but cannot reveal all upstream sample preparation failures.
In the published KoMa example, the researchers incorporated virus-like particles containing artificial RNA into the extraction workflow before the subsequent amplification analysis.
The published method describes adding KoMa VLP suspension to lysis buffer before introducing the clinical specimen in the specified extraction protocol.
Because the control material underwent extraction and downstream RT-PCR, a substantial deviation in its expected amplification behavior could indicate problems associated with sample processing or inhibition.
The article reported an expected KoMa Ct value near 32 under its described experimental conditions. This was a protocol-specific reference, not a universal acceptance threshold for all KoMa implementations.
The ability to monitor multiple analytical stages is valuable, but it also creates an interpretation boundary. A shift in the control signal does not, by itself, identify which exact stage caused the deviation.
What a change in KoMa Ct can reveal
In quantitative real-time PCR, the threshold cycle describes when fluorescence reaches a defined detection criterion. A later Ct can be consistent with less amplifiable material or less efficient amplification under otherwise comparable conditions.
For an exogenous control introduced in a standardized amount, researchers can establish an expected response across appropriately processed samples.
If the observed KoMa signal differs substantially from that expectation, an analytical disturbance may be present. Potential explanations include inefficient extraction, reaction inhibition or another workflow problem.
The published study evaluated KoMa performance across clinical specimens and used its amplification behavior to support interpretation of the SARS-CoV-2 detection assays.
A critical qualification is that the control signal was not independent of every feature of the multiplex reaction. Strong viral target amplification could affect detection of KoMa in the same reaction.
A control signal must be compared with assay-specific expected behavior. A delayed or missing signal should not be interpreted using an arbitrary Ct cutoff borrowed from another experiment.
This highlights the difference between observing a control and validating a control. The first produces a measurement. The second establishes what the measurement means within a defined analytical system.
Why KoMa may disappear when the viral target is strongly positive
One particularly instructive finding from the published study concerns samples containing high concentrations of SARS-CoV-2 RNA.
In the E-gene and KoMa duplex reaction, both assays shared a reaction environment. When viral target abundance was very high, KoMa amplification was not always reliably detectable.
The researchers considered this behavior acceptable for clearly positive specimens within their qualitative diagnostic interpretation framework.
The reasoning is important. If a viral target is strongly detected, the positive finding itself demonstrates that the target amplification system was able to function in that reaction.
However, in a target-negative sample, absence of KoMa amplification creates a different situation. Without the expected control signal, inhibition or other technical failure cannot be confidently excluded.
| Viral target | KoMa signal | Interpretation in the published context |
|---|---|---|
| Not detected | Within expected limits | Supports a negative interpretation, subject to other assay criteria |
| Not detected | Unexpectedly delayed or absent | Potential inhibition or processing issue requiring investigation |
| Strongly detected | Reduced or absent | May occur through multiplex competition and can be acceptable under validated rules |
This observation prevents a common oversimplification. An internal control does not always have to produce the same signal in every sample regardless of target abundance.
What matters is whether the interpretation reflects validated behavior of the particular multiplex assay.
What the first 3,600 specimens contributed to the study
Beyond presenting the molecular design, the researchers described their experience with the first 3,600 clinical specimens analyzed using the RKI/ZBS1 protocol.
This dataset provided practical information about the behavior of the two SARS-CoV-2 assays and their associated control systems under routine sample testing conditions.
The article's Ct distribution analysis showed the relatively consistent amplification behavior of KoMa alongside a wider distribution of c-myc results, reflecting variability in sample-derived nucleic acid.
The distinction matters because KoMa was introduced as a standardized control material, whereas c-myc originated from biological specimens containing differing quantities of human material.
The study illustrates why a controlled exogenous input and an endogenous human target cannot always be interpreted in the same way.
A relatively consistent artificial control helps establish technical expectations. A variable endogenous marker may reveal differences in specimen composition as well as technical factors.
The authors also evaluated the protocol across several real-time PCR instruments. These comparisons highlighted that control detection and multiplex behavior could depend on the instrument and reaction conditions, reinforcing the need for system-specific validation.
What KoMa teaches us about PCR assay validation
The scientific value of KoMa extends beyond the particular SARS-CoV-2 protocol in which it was described.
The example illustrates how internal controls should be selected according to the technical stages that matter for the experimental question.
A DNA template added directly to PCR may be appropriate for assessing amplification, whereas an RNA-containing control introduced before extraction can potentially monitor additional stages relevant to RT-PCR testing.
However, designing a successful control also requires attention to concentration, competition between targets, nucleic acid stability, detection chemistry and assay sensitivity.
The 2025 MIQE 2.0 guidelines provide a modern framework for reporting quantitative PCR experiments, including sample preparation, validation and controls.
The recommendations emphasize that internal controls do not replace other essential quality measures. External positive controls, negative controls and suitable process checks may each address different failure modes.
| Quality question | Relevant experimental approach |
|---|---|
| Did unintended contamination occur? | No-template and suitable negative controls |
| Was amplification inhibited? | Validated internal amplification control |
| Was sample processing successful? | Appropriate pre-extraction process control |
| Was biological material recovered? | Validated endogenous sample marker |
| Did the complete assay perform as expected? | Integrated validation and positive and negative controls |
The broader lesson is that controls should be chosen according to the uncertainties they can address. An assay containing many controls is not automatically better than one containing carefully selected controls with clearly defined interpretation criteria.
A scientifically useful control must provide actionable information about the reliability of the measurement.
What cannot be concluded from the published KoMa study
A peer-reviewed publication provides evidence about a particular experimental system. It does not automatically establish that the described control will behave identically in every assay or biological matrix.
The published KoMa implementation used specific virus-like particles, extraction conditions, primer and probe sequences, fluorescence channels and RT-PCR reaction arrangements.
Changes to those conditions may alter control recovery, amplification efficiency or interaction with the principal target.
The study therefore should not be interpreted as proof of universal compatibility with unrelated extraction methods, laboratory instruments or commercially available PCR kits.
Likewise, the protocol-specific expected KoMa Ct should not be transferred directly into another method as an acceptance threshold.
In this article, KoMa refers specifically to the artificial control sequence and virus-like particle system described in the cited RKI publications. No unverified commercial product specification, catalogue reference or performance claim is implied.
These boundaries are important for scientific communication. Responsible interpretation means distinguishing observations supported by the publication from applications that would require independent experimental validation.
Internal controls turn molecular detection into more trustworthy evidence
Modern biotechnology increasingly depends on sensitive nucleic acid amplification methods to investigate biological systems, engineered cells, environmental specimens and molecular processes.
These methods can detect very small quantities of genetic material, but their sensitivity also makes quality assurance essential.
The published KoMa example demonstrates that reliable molecular interpretation depends not only on the target being measured but also on understanding how the sample and reaction behaved throughout the analytical process.
By combining target detection with internal controls and a human sample marker, the RKI/ZBS1 protocol provided several complementary observations rather than relying on one amplification signal alone.
The same experimental logic can guide the development of new molecular assays. Researchers should identify potential failure points, introduce controls capable of informing those uncertainties and define interpretation rules through validation.
This approach is particularly valuable as laboratories adopt automated extraction, multiplex real-time PCR, high-throughput workflows and increasingly complex analytical technologies.
The long-term contribution of internal controls is therefore conceptual as well as technical. They encourage laboratories to treat molecular results as measurements that require supporting evidence, rather than isolated positive or negative signals.
For biotechnology research, this is the foundation of reproducibility: connecting the molecular signal to a validated experimental process, then interpreting the result within the boundaries of what the method can demonstrate.
Explore the experimental principles, quality controls and laboratory methods that support reliable molecular biology and modern biotechnology research.
Scientific Subjects | Research Products | Contact KomaGene Biotech